bioRxivCell BiologyPreprint
Identification of Omaveloxolone as An Endoplasmic Reticulum Associated Degradation Inhibitor That Induces Early Apoptotic Signaling in Multiple Myeloma
Erin M. KroppiD, Sho Matono, Olivia Y. Wang, Aaron M. RobidaiD, Malathi KandarpaiD, Jineigh L. Grant, Bryndon J. Oleson, Andrew J. Alt, Moshe TalpaziD, Matthew James PiankoiD, Qing LiiD
Abstract
Endoplasmic reticulum-associated degradation (ERAD) is essential for maintaining protein homeostasis, yet its regulatory mechanisms remain poorly understood. A major challenge in studying ERAD is the lack of specific inhibitors targeting the ERAD complex. To address this, we conducted a cell-based high-throughput screen using the FDA-repurposing library and identified omaveloxolone (RTA408) as a potent ERAD inhibitor that selectively impairs the degradation of ER luminal and membrane substrates. Beyond its utility in identifying ERAD substrates, RTA408 exhibits strong cytotoxic effects in multiple myeloma (MM), an incurable plasma cell malignancy. RTA408 inhibits ERAD activity and rapidly induces apoptotic signaling via caspase 8 and the death-inducing signaling complex (DISC). Notably, RTA408 is cytotoxic to malignant plasma cells, including those resistant to proteasome inhibitors, and demonstrates in vivo anti-myeloma activity. Our findings establish ERAD inhibitors as valuable tools for dissecting ERAD regulation while also highlighting their potential as therapeutic agents for MM. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=140 SRC="FIGDIR/small/646787v1_ufig1.gif" ALT="Figure 1"> View larger version (56K): org.highwire.dtl.DTLVardef@96254aorg.highwire.dtl.DTLVardef@16a3f6dorg.highwire.dtl.DTLVardef@6a1503org.highwire.dtl.DTLVardef@897c45_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsO_LIWe developed a cell-based screening approach to identify novel modulators of endoplasmic reticulum associated degradation (ERAD), with implications in studying ERAD biology and targeting plasma cell neoplasms. C_LIO_LIScreening of the FDA-repurposing library identified Omaveloxolone (RTA408) as an inhibitor of luminal and membrane ERAD substrate degradation, which can be leveraged to identify ERAD substrates. C_LIO_LImaveloxolone treatment rapidly induces the unfolded protein response and apoptosis that is dependent on caspase 8 and death-inducing signaling complex (DISC) in multiple myeloma cells. C_LIO_LImaveloxolone exhibits cytotoxic effects against multiple myeloma cells in vitro and in vivo and induces apoptosis in primary plasma cells from patients with relapsed/refractory myeloma C_LI
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Disruption of IRE1α through its Kinase Domain Attenuates Multiple Myeloma
Jonathan M Harnoss, Adrien Le Thomas, … Avi Ashkenazi·bioRxiv·Dec 14, 2018
- A new efficacious Mcl-1 inhibitor maximizes bortezomib and venetoclax responsiveness in resistant multiple myeloma cells
O. S. F. Al Odat, K. Gowda, … M. K. Pandey·bioRxiv·Dec 6, 2023
- Multiple Myeloma: Combination Therapy of BET Proteolysis Targeting Chimeric Molecule with CDK9 Inhibitor
S. L. Lim, P. Koeffler, … W. J. Chng·bioRxiv·Apr 8, 2020
- Constitutive protein degradation induces acute cell death via proteolysis products
S.-H. Chen, S. Prakash, … I. E. Wertz·bioRxiv·Feb 6, 2023
- The Sec61 translocon is a therapeutic vulnerability in Multiple Myeloma
A. Domenger, C. Choisy, … C. Demangel·bioRxiv·Sep 5, 2021
- Novel SLAMF1-derived peptide induces apoptosis in multiple myeloma cells by targeting IRF4 transcription factor for degradation
Ingvild Bergdal Mestvedt, Eline Menu, … Maria Yurchenko·bioRxiv·May 7, 2025